Holen Sie sich die Stockscreener-App
4.53
2.49%
0.11
Vorhandelsmarkt:
4.54
0.010
+0.22%
Schlusskurs vom Vortag:
$4.42
Offen:
$4.46
24-Stunden-Volumen:
2.98M
Relative Volume:
1.66
Marktkapitalisierung:
$490.80M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-8.7115
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+69.66%
1M Leistung:
+47.56%
6M Leistung:
+179.63%
1J Leistung:
+74.23%
1-Tages-Spanne:
$4.1401
$4.685
1-Wochen-Bereich:
$2.61
$4.89
52-Wochen-Spanne:
$1.05
$4.89
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Vergleichen Sie ACRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
4.53 | 478.89M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-05-28 | Eingeleitet | Wedbush | Outperform |
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment - MSN
Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright - MarketBeat
ACRS: Analyst Maintains Buy Rating and $16 Price Target | ACRS S - GuruFocus
Income Plays: What are the future prospects of Aclaris Therapeutics IncWeekly Profit Analysis & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 1-Year HighHere's What Happened - MarketBeat
Aclaris Pushes New Antibody Into Skin Disease Trial, Eyes Asthma Next - mychesco.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Can Aclaris Therapeutics Inc. (8AT) stock withstand sector downturnsMarket Activity Report & High Accuracy Investment Entry Signals - bollywoodhelpline.com
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 - Yahoo Finance
Aclaris begins phase 1b trial of ATI-052 for atopic dermatitis - Investing.com Nigeria
Aclaris begins phase 1b trial of ATI-052 for atopic dermatitis By Investing.com - Investing.com South Africa
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 - The Manila Times
Aclaris Therapeutics, Inc Updates Corporate Overview Presentation - TradingView — Track All Markets
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept - GlobeNewswire
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Why Aclaris Therapeutics Inc. stock could rally in 2025Entry Point & Precise Trade Entry Recommendations - Улправда
Will Aclaris Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Earnings & Daily Profit Focused Screening - Улправда
Early trial data puts Aclaris’ ATI-052 on fast track toward bigger bets - MSN
What valuation multiples suggest for Aclaris Therapeutics Inc. stockWeekly Stock Analysis & Long-Term Growth Plans - Улправда
Is Aclaris Therapeutics Inc. stock affected by interest rate hikesTrade Exit Report & Precise Swing Trade Alerts - Улправда
How Aclaris Therapeutics Inc. stock benefits from strong dollar2025 Breakouts & Breakdowns & AI Powered Trade Plan Recommendations - ulpravda.ru
Market Recap: Can Aclaris Therapeutics Inc. (8AT) stock withstand sector downturnsJuly 2025 Pullbacks & Intraday High Probability Alerts - Улправда
Is Aclaris Therapeutics Inc. stock attractive for passive investorsBond Market & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
Why analysts upgrade Aclaris Therapeutics Inc. stockMarket Sentiment Summary & Reliable Momentum Entry Alerts - Улправда
Aclaris joins Nasdaq biotech index, marking milestone for clinical-stage firm - MSN
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets - mychesco.com
The week in pharma: action, reaction and insight – week to January 19, 2024 - The Pharma Letter
Aclaris Therapeutics Reports Positive Interim Phase 1a ATI-052 Data, Speeds Up Development Plans - Defense World
Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target By Investing.com - Investing.com South Africa
Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target - Investing.com Nigeria
Aclaris Therapeutics Reports Positive Phase 1a Data For ATI-052 - Nasdaq
Aclaris advances ATI-052 after positive Phase 1a results - TipRanks
Aclaris reports positive results for anti-inflammatory drug ATI-052 By Investing.com - Investing.com South Africa
Aclaris Therapeutics Announces Positive Interim Results from Phase 1a Trial of ATI-052 - TradingView — Track All Markets
ACRS: ATI-052 showed best-in-class potential in phase 1a, enabling rapid advancement to phase 1b trials - TradingView — Track All Markets
Aclaris Therapeutics Reports Positive Interim Results for ATI-052 Phase 1a Trials and Outlines Future Development Plans - Quiver Quantitative
New Aclaris antibody shows potential for 3‑month dosing in skin and asthma care - Stock Titan
What analysts say about Aclaris Therapeutics Inc 8AT stockStock Market Trends & Affordable Portfolio Trading - earlytimes.in
Hair Loss Treatment Market Booming with Rapid Growth Through 2032 | Viviscal, Cipla Inc., Aclaris Therapeutics, Inc. - openPR.com
Three Bridge Wealth Advisors LLC Takes Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Why Aclaris Therapeutics Inc. stock remains undervaluedMoving Average Strategies & Exceptional Profit Trading - bollywoodhelpline.com
Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
What drives Aclaris Therapeutics Inc stock priceEarnings Forecast Updates & Big Profit Low Trading - earlytimes.in
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.46%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):